Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RRx-001 and Nivolumab in Advanced Solid Tumors or Lymphomas
NCT02518958Phase 1Completed
- Sponsor
- EpicentRx
- Start
- Jul 2015
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Nibrozetone in solid tumor and lymphoma, sponsored by EpicentRx. Primary endpoint: Number, frequency and type of adverse events at 23 weeks. Started Jul 2015; status: completed.
02
Drugs
Nibrozetone
03
Conditions
solid tumorlymphoma
Beyond the preview
Go deeper on NCT02518958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02518958.